OKYO Pharma Limited(OKYO)

Biotechnology · London, GL

$1.46-0.01 (-0.68%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T21:08:00.185Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:08:00.185Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 56,015,925
Total debt · period ending 2026-03-31: 0
Cash · period ending 2026-03-31: 14,594,268
TTM revenue · period ending 2026-03-31: N/A

FMP input reference: fae3dac89f6aae568c3e1e6131ec6a0b9ed594063ed7dd46d2bf25dadf8b5230

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

OKYO EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

OKYO Competitors' EV/Sales Ratio

OKYO

OKYO Pharma Limited

Current

Market Cap

$56.02M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALDX

Aldeyra The

vs OKYO

Market Cap

$55.25M

EV/Sales Ratio

N/A

TTM Avg

3.74x

3Y Avg

3.42x

5Y Avg

3.42x

CNTB

Connect Biopharma Holdings Limited

vs OKYO

Market Cap

$57.01M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TLPH

Talphera, Inc.

vs OKYO

Market Cap

$57.61M

EV/Sales Ratio

56866.56x

TTM Avg

24657.57x

3Y Avg

9404.59x

5Y Avg

5624.70x

BOLD

Boundless Bio, Inc.

vs OKYO

Market Cap

$57.76M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RANI

Rani Therapeutics Holdings, Inc.

vs OKYO

Market Cap

$54.14M

EV/Sales Ratio

10.83x

TTM Avg

51.21x

3Y Avg

45.57x

5Y Avg

60.27x

KLRS

Kalaris Therapeutics Inc

vs OKYO

Market Cap

$58.06M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INKT

MiNK Therapeutics, Inc.

vs OKYO

Market Cap

$58.29M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NMAD

NOMAD Power Solutions, Inc.

vs OKYO

Market Cap

$53.70M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACET

Adicet Bio, Inc.

vs OKYO

Market Cap

$58.43M

EV/Sales Ratio

N/A

TTM Avg

8.16x

3Y Avg

93.50x

5Y Avg

96.95x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
OKYO Pharma Limited (OKYO)	$56.02M	N/A	N/A	N/A	N/A
Aldeyra The (ALDX)vs ›	$55.25M	N/A	3.74x	3.42x	3.42x
Connect Biopharma Holdings Limited (CNTB)vs ›	$57.01M	N/A	N/A	N/A	N/A
Talphera, Inc. (TLPH)vs ›	$57.61M	56866.56x	24657.57x	9404.59x	5624.70x
Boundless Bio, Inc. (BOLD)vs ›	$57.76M	N/A	N/A	N/A	N/A
Rani Therapeutics Holdings, Inc. (RANI)vs ›	$54.14M	10.83x	51.21x	45.57x	60.27x
Kalaris Therapeutics Inc (KLRS)vs ›	$58.06M	N/A	N/A	N/A	N/A
MiNK Therapeutics, Inc. (INKT)vs ›	$58.29M	N/A	N/A	N/A	N/A
NOMAD Power Solutions, Inc. (NMAD)vs ›	$53.70M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$58.43M	N/A	8.16x	93.50x	96.95x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics